TD Cowen maintains Alnylam Pharmaceuticals at Buy, lowers price target to $354 from $482
TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, citing a 26.6% reduction. The new target suggests a 103.4% upside from the Oct 29 closing price of $174. Recent analyst price targets for the company range from $199 to $320.
How this was made
The 30-second read
Why it matters
The target cut reflects concerns about growth prospects, likely prompting short‑term sell pressure.
Market read
Analyst target changes are a common catalyst for biotech stock moves, making this a modest‑impact news item.
What to watch
Potential upcoming clinical data or partnership announcements could offset the target reduction.
Background
Alnylam is a leading RNAi therapeutics company; analyst coverage influences biotech sentiment.
Ticker impact
TD Cowen lowered its price target on Alnylam Pharmaceuticals to $354 from $482, indicating a downgrade.
downward pressure as investors price in the lower target.
Target reductions are a direct catalyst for short‑term price declines.
Market effects
May weigh on other RNA‑therapeutics peers as analysts reassess sector valuations.
Limited to US biotech space; no broader regional effect.
Minimal global impact beyond biotech investors.
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity at lower levels.
Key entities
- AnalystTD Cowen
Equity research firm providing the revised target.
